İmmün Yetmezlikli Hastalarda Görülen Enfeksiyonlar

Yıl 2005, Cilt: 3 Sayı: 1, 40 - 46, 01.06.2005

Sara Şebnem Kılıç

Öz

Antikor yapım defekti en sık görülen immün yetmezlik grubudur. Bu hastalık grubu tüm immünglobulinlerin düşük olduğu agammaglobulinemi gibi ağır hastalık tablolarını içerebildiği gibi daha hafif klinik seyirli normal immunglobulin seviyelerine sahip ancak spesifik antikor eksikliği olan hastaları da içerebilmektedir 1,2 . Humoral immün yetmezlikler tüm immün yetmezliklerin %60 kadarını oluşturmaktadır.

Kaynakça

• Fleisher TA, Bleesing JJ. Immune function. Pediatr Clin North Am. 2000;47:1197-209.
• Sorensen RU, Moore C. Antibody deficiency syndromes. Pediatr Clin North Am. 2000; 47:1225-52.
• Anonymous. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol 1999; 118(Suppl. 1):1-28.
• Report of a WHO scientific group: Primary immunodeficiency diseases. Clin Exp Immunol 1997;109, Suppl 1:1-28.
• Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000;343: 1313-24.
• Bruton OC. Agammaglobulinemia. Pediatr 1952; 9: 722-8.
• Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinemia. Clin Rev Allergy Immunol 2000;19:183-204.
• Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobuline- mia. Cell 1993;72:279-90.
• Curtin JJ, Webster AD, Farrant J, Katz D. Bronchiectasis in hypogam- maglobulinaemia – a computed tomography assessment. Clin Radiol 1991;44:82-4.
• Wilfert CM, Buckley RH, Rosen FS, et al. Persistent enterovirus infecti- ons in agammaglobulinemia. In: Schessinger D (Editor), Microbiology. Washington, DC:ASM, 1977; p.488.
• Schaffer FM, Monteiro RC, Volanakis JE, Cooper MD. IgA deficiency. Immunodef Rev 1991;3:15-44.
• Cunningham-Rundles C, Bodian C. Common variable immunodefici- ency: clinical and immunological features of 248 patients. Clin Immunol 1999;92:34-48.
• Hausser C, Virelizier JL, Buriot D, Griscelli C . Common variable hypo- gammaglobulinemia in children. Am J Dis Child 1983;137:833-7.
• Cunningam-Rundles C. Clinical and immunologic analyses of 103 pati- ents with common variable immunodeficiency. J Clin Immunol 1989;9:22-33.
• Buckley RH. Advances in the understanding and treatment of human severe combined immunodeficiency. Immunol Res 2001;22:237-51.
• Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immu- nodeficiency (SCID): Genetic, phenotypic and functional diversity in 108 infants. J Pediatr 1997;130:378-387.
• DiGeorge AM. Congenital absence of the thymus and its immunologic consequences: concurrence with congenital hypoparathyroidism. In: Bergsma D, ed. Birth defects original article series 1968. Vol 4. White
• fiekil 1: Oral candidiasis. Plains, NY: National Foundation March of Dimes, 116.
• De la Chapelle A, Herva R, Koivisto M, Aula P. A deletion in chromoso- me 22 can cause DiGeorge syndrome. Hum Genet 1981;57:253-6.
• Hong R. The DiGeorge anomaly. Semin Hematol 1998;35:282-90.
• Cuneo BF. 22q11.2 deletion syndrome: DiGeorge, velocardiofacial, and conotruncal anomaly face syndromes. Curr Opin Pediatr. 2001;13:465- 72.
• Jawad AF, McDonald-Mcginn DM, Zackai E, Sullivan KE. Immunologic features of chromosome 22q11.2 deletion syndrome (DiGeorge syndro- me/velocardiofacial syndrome). J Pediatr 2001;139:715-23.
• Tobias ES, Morrison N, Whiteford ML, Tolmie JL. Towards earlier diag- nosis of 22q11 deletion. Arch Dis Child 1999; 81:513-14.
• Demczuk S, Aurias A. DiGeorge syndrome and related syndromes as- sociated with 22q11.2 deletions. Ann Genet 1995;38:59-76.
• Matsumo T, Amamoto N, Kondoh T, Nakayama M, Takayanagi T and Tsuji Y. Complete DiGeorge syndrome treated by bone marrow transp- lantation. Bone Marrow Transplant 1998;22:927-30.
• Markert ML, Boeck A, Hale LP et al. Transplantation of thymus tissue in complete DiGeorge syndrome. N Eng J Med 1999;341:1180-9.
• Puck JM, Deschenes SM, Porter JC, et al. The interleukin-2 receptor gamma chain maps to Xq13.1 and is mutated in X-linked severe combi- ned immunodeficiency, SCIDX1. Hum Mol Gen 1993;2:1099-104.
• Noguchi M, Yi H, Rosenblatt HM, et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993;73:147-157.
• Schwarz K, Gauss GH, Ludwig L, et al. RAG mutations in human B cell- negative SCID. Science 1996;274:97-99.
• Kung C, Pingel JT, Heikinheimo M, et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodefi- ciency disease. Nat Med 2000;6:43-345.
• Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem cell transp- lantation for the treatment of severe combined immunodeficiency. N Engl J Med 1999;340:508-516.
• Derry JMJ, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott–Aldrich syndrome. Cell 1994;78:635-644. Erratum: 79: 922a.
• Haddad E, Zugaza JL, Louache F, et al. The interaction between Cdc42 and WASP is required for SDF-1-induced T-lymphocyte chemotaxis. Blood 2001;97:33-38.
• Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiati- on and in cell growth control. Genes Dev 1996;10:2401-10.
• Heintz N. Ataxia telangiectasia: cell signaling, cell death and the cell cycle. Curr Opin Neurol 1996;9:137-140.
• Kirkpatrick CH. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J. 2001;20:197-206.
• Lilic D. New perspectives on the immunology of chronic mucocutane- ous candidiasis. Curr Opin Infect Dis. 2002;15:143-7.
• Ree T, Jennings PR, Ofotokun I. Chronic mucocutaneous candidiasis. JAAPA. 2002;15:67-70.
• Coleman R, Hay RJ. Chronic mucocutaneous candidosis associated with hypothyroidism: a distinct syndrome? Br J Dermatol 1997;136:24-9.
• de Moraes-Vasconcelos D, Orii NM, Romano CC, Iqueoka RY, Duarte AJ. Characterization of the cellular immune function of patients with chronic mucocutaneous candidiasis. Clin Exp Immunol. 2001;123:247- 53.
• Lilic D, Gravenor I, Robson N et al. Deregulated production of protecti- ve cytokines in response to Candida albicans infection in patients with chronic mucocutaneous candidiasis. Infect Immun. 2003;71:5690-9.
• Lilic D, Cant AJ, Abinun M, Calvert JE, Spickett GP. Chronic mucocuta- neous candidiasis. I. Altered antigen-stimulated IL-2, IL-4, IL-6 and in- terferon-gamma (IFN-gamma) production. Clin Exp Immunol. 1996;105:205-12.
• Lilic D, Calvert JE, Cant AJ, Abinun M, Spickett GP. Chronic mucocuta- neous candidiasis. II. Class and subclass of specific antibody respon- ses in vivo and in vitro. Clin Exp Immunol. 1996;105:213-9.
• Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocuta- neous candidiasis with selective antibody deficiency. Ann Allergy Asthma Immunol. 2003;90:259-64.
• Palma-Carlos AG, Palma-Carlos ML, da Silva SL. Natural killer (NK) cells in mucocutaneous candidiasis. Allerg Immunol. 2002;34:208-12.
• Zuccarello D, Salpietro DC, Gangemi S et al. Familial chronic nail can- didiasis with ICAM-1 deficiency: a new form of chronic mucocutane- ous candidiasis. J Med Genet. 2002;39:671-5.
• Vazquez JA, Sobel JD. Mucosal candidiasis. Infect Dis Clin North Am. 2002;16:793-820.
• Rowen JL. Mucocutaneous candidiasis. Semin Perinatol. 2003;27:406- 13.
• Jorizzo JL, Sams WM Jr, Jegasothy BV, Olansky AJ. Cimetidine as an immunomodulator: chronic mucocutaneous candidiasis as a model. Ann Intern Med. 1980;92:192-5.
• Polizzi B, Origgi L, Zuccaro G, Matti P, Scorza R. Case report: success- ful treatment with cimetidine and zinc sulphate in chronic mucocuta- neous candidiasis. Am J Med Sci. 1996;311:189-90.
• Hong R. Reconstitution of T-cell deficiency by thymic hormone or thy- mus transplantation therapy. Clin Immunol Immunopathol. 1986;40:136- 41.
• Ballow M, Hyman LR. Combination immunotherapy in chronic mucocu- taneous candidiasis. Synergism between transfer factor and fetal thy- mus tissue. Clin Immunol Immunopathol. 1977;8:504-12.
• Hoh MC, Lin HP, Chan LL, Lam SK. Successful allogeneic bone marrow transplantation in severe chronic mucocutaneous candidiasis syndro- me. Bone Marrow Transplant. 1996;18:797-800.
• Buckley RH. The hyper-IgE syndrome. Clin Rev Allerg Immunol 2001,20:139-54.
• Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobuline- mia -E and undue susceptibility to infection. Pediatrics 1972;49:59-70.
• Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with re- current infections – an autosomal dominant multisystem disorder. N Engl J Med 1999;340:692-702.
• Grimbacher B, Schaffer AA, Holland SM et al. Genetic linkage of hyper- IgE syndrome to chromosome 4. Am J Hum Genet. 1999; 65:735-44.
• Grimbacher B, Holland SM, Puck JM.Hyper-IgE syndromes. Immunol Rev. 2005;203:244-50.
• Davis SD, Schaller J, Wedgwood RJ. Recurrent, 'cold', staphylococcal abscesses (Job's) syndrome Lancet 1966;1:1013-15.
• Hill HR, Ochs HD, Quie PG et al. Defect in neutrophil granulocyte che- motaxis in Job’s syndrome of recurrent ‘‘cold’’ staphylococcal absces- ses. Lancet 1974;2:617-9.
• Donabedian H, Gallin JI. The hyperimmunoglobulin E recurrent infecti- on (Job’s) syndrome: a review of the NIH experience and the literatu- re. Medicine 1983;62:195-208.
• Renner ED, Puck JM, Holland SM et al. Autosomal recessive hyperim- munoglobulin E syndrome: a distinct disease entity. J Pediatr 2004;144:93-99.
• Leung DY, Geha RS. Clinical and immunologic aspects of the hyperim- munoglobulin E syndrome. Hematol Oncol Clin North Am. 1988;2:81-100.
• Erlewyn-Lajeunesse MD. Hyperimmunoglobulin-E syndrome with re- current infection: a review of current opinion and treatment. Pediatr Allergy Immunol. 2000;11:133-41.
• Vercelli D, Jabara HH, Cunningham-Rundles C, et al. Regulation of im- munoglobulin (Ig)E synthesis in the hyper-IgE syndrome. J Clin Invest. 1990;85:1666-71.
• Herrod HG, Erffmeyer JE, Valenski WR. Elevated in vitro IL-4 producti- on in a patient with elevated serum IgE. Ann Allergy. 1994;73:444-8.
• Saini SS, Klion AD, Holland SM, Hamilton RG, Bochner BS, Macglashan DW Jr. The relationship between serum IgE and surface levels of Fcep- silonR on human leukocytes in various diseases: correlation of expres- sion with FcepsilonRI on basophils but not on monocytes or eosinop- hils. J Allergy Clin Immunol. 2000;106:514-20.
• Garraud O, Mollis SN, Holland SM, et al. Regulation of immunoglobulin production in hyper-IgE (Job's) syndrome. J Allergy Clin Immunol. 1999;103 (2 Pt 1):333-40.
• Claasen JJ, Levine AD, Schiff SE, Buckley RH. Mononuclear cells from patients with the hyper-IgE syndrome produce little IgE when they are stimulated with recombinant human interleukin-4. J Allergy Clin Immu- nol. 1991;88:713-21.
• Van Scoy RE, Hill HR, Ritts RE, Quie PG. Familial neutrophil chemotaxis defect, recurrent bacterial infections, mucocutaneous candidiasis, and hyperimmunoglobulinemia E. Ann Intern Med 1975;82:766-71.
• Ito R, Mori M, Katakura S, et al. Selective insufficiency of IFN-gamma secretion in patients with hyper-IgE syndrome. Allergy. 2003;58:329-36.
• Borges WG, Augustine NH, Hill HR. Defective interleukin-12/interferon- gamma pathway in patients with hyperimmunoglobulinemia E syndro- me. J Pediatr 2000;136:176-80.
• Paganelli R, Scala E, Capobianchi MR, et al. Selective deficiency of in- terferon-gamma production in the hyper-IgE syndrome. Relationship to in vitro IgE synthesis. Clin Exp Immunol. 1991;84:28-33.
• Ohga S, Nomura A, Ihara K, et al. Cytokine imbalance in hyper-IgE syndrome: reduced expression of transforming growth factor beta and interferon gamma genes in circulating activated T cells Br. J. Haema- tol 2003;121: 324-21.
• Chehimi J, Elder M, Greene J et al. Cytokine and chemokine dysregula- tion in hyper-IgE syndrome. Clin Immunol. 2001;100:49-56.
• Hsu CT, Lin YT, Yang YH, Chiang BL. The hyperimmunoglobulin E syndrome. J Microbiol Immunol Infect. 2004;37:121-3.
• Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol. 1998;81:153-8.
• Winkelstein JA, Marino MC, Johnston Jr RB, et al. Chronic granuloma- tous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155-69.
• Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000;343:1703-14.
• Fischer A, Lisowska-Grospierre B, Anderson DC, Springer TA. Leukocy- te adhesion de.ciency: molecular basis and functional consequences. Immunodef Rev 1988;1:39-54.
• Etzioni A. Adhesion molecule de.ciencies and their clinical signi.cance. Cell Adhesion Commun 1994;2:257-260.
• Kishimoto TK, Springer TA. Human leukocyte adhesion deficiency: mo- lecular basis for a defective immune response to infections of the skin. Curr Probl Dermatol 1989;18:106.
• Figueroa JE, Densen P. Infectious diseases associated with comple- ment deficiencies. Clin Microbiol Rev 1991;4:359.
• Winkelstein JA, Sullivan KE, Colten HR. Genetically determined defici- encies of complement. In: Scriver CR, Beaudet AL, Sly WS, Valle DL (Editors). Metabolic Basis of Inherited Disease. New York, McGraw- Hill, 1995; pp. 3912-3941.
• Westberg J, Fredrikson GN, Truedsson L, Sjoholm AG, Uhlen M. Sequ- ence-based analysis of properdin deficiency: identification of point mutations in two phenotypic forms of an X-linked immunodeficiency. Genomics 1995;29:1-8.
• Ozbek N, Fieschi C, Yilmaz BT, de Beaucoudrey L, Demirhan B, Feinberg J, Bikmaz YE, Casanova JL.Interleukin-12 receptor beta 1 chain defici- ency in a child with disseminated tuberculosis. Clin Infect Dis. 2005;40:55-8.
• Dorman SE, Picard C, Lammas D, Heyne K, van Dissel JT, Baretto R, Ro- senzweig SD, Newport M, Levin M, Roesler J, Kumararatne D, Casano- va JL, Holland SM. Clinical features of dominant and recessive interfe- ron gamma receptor 1 deficiencies. Lancet. 2004;364:2113-21.